drugset / Trial / NCT07195799
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, non-randomized, multi-cohort study to evaluate the efficacy and safety of linperlisib combined with cyclophosphamide, prednisone, and thalidomide (CPT) regimen in the treatment of relapsed and/or refractory non-Hodgkin lymphoma.
Timeline
- Start
- 2024-12-31
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | — |
| Subject | Linperlisib | Small molecule | 80 mg | — |
| Subject | Prednisone | Other / unclassified | 20 mg | — |
| Subject | Thalidomide | Other / unclassified | 50 mg | — |